From MarketBeat:



Jazz Pharmaceuticals plc has received a “Moderate Buy” recommendation from nine analysts, with an average 12-month price objective of $195.50. The company’s stock has been rated with buy and hold ratings by analysts. Director Mark Douglas Smith sold 417 shares of Jazz Pharmaceuticals stock, totalling $49,735.59, and analysts anticipate that Jazz Pharmaceuticals will post 15.38 EPS for the current fiscal year. The company has a debt-to-equity ratio of 1.46, a quick ratio of 1.67, and a current ratio of 2.06. The company has a market cap of $7.63 billion, with a price-to-earnings ratio of 137.79 and a PEG ratio of 1.02. Jazz Pharmaceuticals last released its earnings results showing revenue of $972.14 million in the quarter. The company identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the field of neuroscience and oncology. The stock is currently owned by 88.15% of institutional investors and hedge funds. Despite its “Moderate Buy” rating, the top-rated analysts have identified five other stocks as better buys.



Original: Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Receives Consensus Rating of “Moderate Buy” from Brokerages